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A B S T R A C T
TB Pericarditis is associated with signiﬁcant inﬂammatory and immune responses which can
paradoxically cause injury to the pericardium and myocardium. Management with anti-TB therapy
alone does not prevent complications or reduce mortality. Thus the prevailing view is that adjunct host-
directed therapies such as use of glucocorticoid treatment could attenuate destructive inﬂammatory
responses and improve morbidity and mortality rates. A recent trial showed no advantage of using
adjunct corticosteroid treatment on the combined endpoint of death, cardiac tamponade or constriction.
The current lack of effective medical treatment for reducing the signiﬁcant morbidity and mortality
associated with TB pericarditis, highlights the urgent need for newer approaches to treating the disease.
Newer treatment options for pericarditis using adjunct host-directed therapies, including autologous
bone-marrow-derived Mesenchymal Stromal Cells (MSCs) therapy, now require evaluation in randomized
placebo-controlled controlled trials.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idCardiac diseases are very common causes of inpatient admission
to hospitals and impose a large burden on health services
worldwide.1,2 Pericarditis, inﬂammation of the membranous
pericardial sac surrounding the heart, is a common cause of
pericardial effusion, cardiac tamponade, cardiac failure and
constrictive pericarditis in sub-Saharan Africa (SSA).3 Whilst
infectious pathogens are more common causes of pericarditis there
are other non-communicable diseases that result in pericardial
disease such as cancer, autoimmune diseases, connective tissue
disorders, endocrine, myopericardial diseases and pericardial injury
syndromes.4–8 The relative frequency of different underlying causes
of pericarditis depends on the local epidemiology, the hospital
setting and management protocols in place. Thus the diagnostic and
management algorithms for pericarditis are dependent on the
background prevalence of the underlying aetiology. Many cases still
remain idiopathic in developed countries, whereas tuberculosis, HIV
infection and associated opportunistic infections are important
causes in high TB and HIV endemic countries.6,9,10
A spectrum of bacterial and viral pathogens cause pericarditis,
although it is assumed in sub-Saharan Africa (SSA) that the
majority of cases of pericarditis are due to tuberculosis (TB), some* Corresponding author. Therapeutic Immunology, Department of Laboratory
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).of whom often have concomitant human immunodeﬁciency virus
(HIV) infection.5,9 The treatment of pericardial diseases in SSA is
largely empirical because of the relative lack of randomized trials
compared with other cardiovascular diseases.7,11 The main clinical
forms of pericardial diseases in SSA are subacute pericardial
effusion, effusive constrictive and constrictive pericarditis.8,12
Despite empiric anti-TB therapy, pericardial drainage, or pericar-
diectomy, mortality rates are high (up to 26% at 6 months but is
even higher (40%) among people living with HIV infection).5,7,9
Pericarditis from any cause is associated with signiﬁcant
inﬂammatory and immune responses which can paradoxically
cause injury to the pericardium and myocardium. Management
with antimicrobial therapy alone does not prevent complications
or reduce mortality. Thus the prevailing view is that adjunct host-
directed therapies such as use of glucocorticoid treatment could
attenuate destructive inﬂammatory responses and improve
morbidity and mortality rates.3,6,7 Current guidelines9,10 recom-
mend treatment with glucocorticoids in addition to anti-TB drugs
in patients with TB pericarditis although the evidence base on
which this recommendation was developed remains weak.13
The results of a large placebo-controlled randomized clinical
trial of two host-directed therapies in patients in Africa with
presumed tuberculous pericarditis were published recently.14 The
IMPI (Investigation of the Management of Pericarditis) trial, was a
multicenter, factorial-design trial that randomly assigned
1400 patients with pericarditis (two thirds were HIV-infected)ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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course of 6 weeks or placebo. They were further randomized to
receive placebo or ﬁve injections of heat-killed Mycobacterium
indicus pranii (M.w), an environmental saprophytic mycobacterium
with assumed immunomodulatory effects.15 The study results
were clear - therapy with either intervention had no signiﬁcant
effect on the primary composite efﬁcacy outcome of death, cardiac
tamponade requiring pericardiocentesis, or development of
constrictive pericarditis, and 18% of patients died. Both interven-
tions increased the incidence of cancer among trial participants.
There was an overall reduction in the development of constrictive
pericarditis and in hospitalizations with prednisolone treatment
regardless of HIV status. Thus, it has been suggested that patients
who might beneﬁt from immunomodulatory treatment may
include those with large effusions, those with high levels of
inﬂammatory cells in pericardial ﬂuid, or those with signs of early
constriction.16 In addition, the study also conﬁrmed the long-
standing clinical observation that identiﬁcation of the speciﬁc
microbial etiology of pericarditis when patient presents at point of
care with pericarditis is difﬁcult, since only a quarter of patients in
the study had microbiological conﬁrmation.
A range of innate, adaptive and autoimmune immune responses
are triggered in pericarditis, resulting in acute, sub-acute or chronic
inﬂammation of the pericardium and cardiac tissue.5–12 The cellular
and cytokine responses contribute to pericardial and myocardial
cardiac pathologies which subsequently compromise cardiac
function.7,8,11 Recent advances have focused attention on host-
directed treatment options and provide renewed hope for better
outcomes for infectious diseases associated with excess and
aberrant destructive inﬂammation.17–20 Augmentation or dampen-
ing of pro-inﬂammatory responses could be of value in the
treatment of individuals who exhibit inﬂammation-induced tissue
damage. It may also help revert an unsuccessful immune response
back to a productive response and could induce long-lasting
immune memory capable of providing continuous protection. This
concept is being explored for treatment of cardiac conditions and
immune based cytokine or cellular treatments are now being trialed
for improving treatment outcomes of drug-resistant TB.21–24
Adjunct therapy using the patient’s own bone marrow derived
mesenchymal stromal cells (MSCs) may present a viable option for
treatment of drug resistant TB since they modulate immune
responses with beneﬁcial trophic activity on damaged tissues.17–24
The anti-scarring, and angiogenesis effects of MSCs may improve
management outcomes in both immunocompromised and immu-
nocompetent individuals. The infusion of autologous bone marrow
derived MSCs have been found to be safe and to restore functional
cellular immune responses in a phase 1 trial in Belarus patients
with MDR-TB.25 Host-directed therapies for cytomegalovirus and
Epstein-Barr virus infections, have successfully used genome-scale
gene expression proﬁles and drug-induced re-activation of latent
viral pathogens to determine the optimal timepoints for immune
interventions26
Similar strategies may be used to determine the best timepoint to
offer adjunct therapies for patients with TB pericarditis. The current
lack of effective medical treatment for reducing the signiﬁcant
morbidity and mortality associated with TB pericarditis, highlights
the urgent need for newer approaches to treating the disease. Newer
treatment options for pericarditis, such as cytokine therapies, the
use of re-purposed drugs, or cellular therapy, including the use of
autologous bone-marrow-derived MSCs requires now evaluation in
randomized placebo-controlled controlled trials.
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